WuXi AppTec Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 39,414 full-time employees. The company went IPO on 2018-05-08. WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The firm conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.
根據最新的財務報表(Form-10K),Super Hi International Holding Ltd. 的總資產為 $0,淨損失為 $0
WUXIF 的關鍵財務比率是什麼?
Super Hi International Holding Ltd. 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
WuXi AppTec Co., Ltd. 的收入按細分市場或地理位置如何劃分?
Super Hi International Holding Ltd. の最大収益セグメントは Haidilao Restaurant で、最新の利益発表における収益は 5,831,121,804 です。地域別に見ると、Singapore が Super Hi International Holding Ltd. の主要市場であり、収益は 1,268,621,062 です。
WuXi AppTec Co., Ltd. 是否盈利?
いいえ,根據最新的財務報表,Super Hi International Holding Ltd. 的淨損失為 $0